Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

Blood

Volumn 112, Issue 8, 2008, Pages 3434-3443

  Zhou, Li ^a   Nguyen, Aaron N ^b   Sohal, Davendra ^a   Ma, Jing Ying ^b   Pahanish, Perry ^a,c   Gundabolu, Krishna ^a   Hayman, Josh ^a   Chubak, Adam ^a   Mo, Yongkai ^a   Bhagat, Tushar D ^a   Das, Bhaskar ^a   Kapoun, Ann M ^b   Navas, Tony A ^b   Parmar, Simrit ^c   Kambhampati, Suman ^d   Pellagatti, Andrea ^e   Braunchweig, Ira ^a   Zhang, Ying ^f   Wickrema, Amittha ^g   Medicherla, Satyanarayana ^b   Boultwood, Jacqueline ^e   Platanias, Leonidas C ^h   Higgins, Linda S ^b   List, Alan F ⁱ   Bitzer, Markus ^a   Verma, Amit ^a,c,j   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SCIOS INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j ALBERT EINSTEIN CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; LENTIVIRUS VECTOR; SD 208; SHORT HAIRPIN RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; SD-208; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CD34 SELECTION; CELL CYCLE ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; GENE ACTIVATION; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; AGED; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; LENTIVIRINAE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSGENIC MOUSE;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD34; BONE MARROW; FEMALE; HEMATOPOIESIS; HUMANS; LENTIVIRUS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; PROTEIN-SERINE-THREONINE KINASES; PTERIDINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 54049149411     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-139824     Document Type: Article

References (59)

1. Heaney ML Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.
2. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83:358-368.
3. Greenberg PL. Biologic nature of the myelodysplastic syndromes. Acta Haematol. 1987;78(suppl 1):94-99.
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system tor evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088.
5. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
6. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications tor disease natural history and treatment. Leuk Res. 1998;22: 1123-1136.
7. Westwood NB, Mufti GJ. Apoptosis in the myelodysplastic syndromes. Curr Hematol Rep. 2003; 2:186-192.
8. Ohshima K, Karube K, Shimazaki K, et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma. 2003: 44:1339-1346.
9. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001:115:881-894.
10. Allampallam K, Shetty V, Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol. 2002:75:289-297.
11. Allampallam K, Shetty V, Hussaini S, et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res. 1999:19:5323-5328.
12. Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 2007:131:1789-1793.
13. Akiyama T, Matsunaga T, Terui T, et al. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. Leukemia. 2005;19:1558-1566.
14. Taketazu F, Miyagawa K, Ichijo H, et al. Decreased level of transforming growth factor-beta in blood lymphocytes of patients with aplastic anemia. Growth Factors. 1992;6:85-90.
15. Gyulai Z, Balog A, Borbenyi Z, Mandi Y. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung. 2005; 52:463-475.
16. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96: 2240-2245.
17. Yoon SY, Li CY, Lloyd RV, Tefferi A. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. Int J Hematol. 2000;72:337-342.
18. Verma A, List AF Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep. 2005;4:429-435.
19. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002;277:7726-7735.
20. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokineinduced hemopoietic suppression in aplastic anemia. J Immunol. 2002:168:5984-5988.
21. Sokol L, Gripe L, Kantarjian H, et al. Phase l/lI, randomized, multicenter multicenter, dose, doseascension study of the p38 MAPK inhibitor ascension study of the p38 MAPK inhibitor Scio-469 in patients with myelodysplastic syndromes (MDS) 469. American Society of Hematology. 2006;108:Abstract no. 2657.
22. Wickrema A, Uddin S, Sharma A, et al. Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem. 1999;274:24469-24474.
23. Uhl M, Aulwurm S. Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64:7954-7961.
24. Leung SY, Niimi A, Noble A, et al. Effect of transforming growth factor-beta receptor I kinase inhibitor 2, 4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J Pharmacol Exp Ther. 2006;319:586-594.
25. Gaspar NJ, Li L, Kapoun AM, et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol. 2007;72:152-161.
26. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res. 2006;12:4315-4330.
27. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs. 2006;7:513-521.
28. Hayashi T, Hideshima T, Nguyen AN. et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004;10: 7540-7546.
29. National Center for Biotechnology Information. Gene Expression Omnibus. http://www.ncbi.nlm. nih.gov/geo/. Accessed March 1, 2008.
30. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108:337-345.
31. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (lowrisk) myelodysplastic syndrome. Blood. 2005; 106:2982-2991.
32. Su Al, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101: 6062-6067.
33. Oswald J, Steudel C, Salchert K, et al. Geneexpression profiling of CD34+ hematopoietic cells expanded in a collagen I matrix. Stem Cells. 2006;24:494-500.
34. Eckfeldt CE, Mendenhall EM, Flynn CM, et al. Functional analysis of human hematopoietic stem cell gene expression using zebrafish. PLoS Biol. 2005:3:e254.
35. National Center for Biotechnology Information. UniGene. http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene. Accessed March 1, 2008.
36. KapounAM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94:453-461.
37. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30: e15.
38. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92:2572-2576.
39. Yu L, Hebert MC, Zhang YE. TGF-beta receptoractivated p38 MAP kinase mediates Smadindependent TGF-beta responses. EMBO J. 2002;21:3749-3759.
40. Bhatia M. Molecular Signatures Orchestrating fate of Human Hematopoietic Stem Cells Originating From Different Stages of Ontogeny. http://www.ncbi.nlm. nih.gov/projects/geo/query/acc.cgi?acc=GSE3823.
41. Isufi I, Seetharam M, Zhou L, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27:543-552.
42. Irizarry RA, Warren D, Spencer F, et al. Multiplelaboratory comparison of microarray platforms. Nat Methods. 2005;2:345-350.
43. Dobbin KK. Beer DG, Meyerson M, et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res. 2005;11:565-572.
44. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat Methods. 2005;2:337-344.
45. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Gontrol (MAQG) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006;24:1151-1161.
46. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427-4433.
47. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A. 2004;101:9309-9314.
48. Navas TA, Mohindru M, Estes M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006;108:4170-4177.
49. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
50. Legare RD, Gilliland DG. Myelodysplastic syndrome. Curr Opin Hematol. 1995;2:283-292.
51. Hu X, Zuckerman KS. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res. 2001;10:67-74.
52. Imai Y, Kurokawa M. Izutsu K, et al. Mutations of the Smad4 gene in acute myelogeneous leukemia and theirfunctional implications in leukemogenesis. Oncogene. 2001;20:88-96.
53. Wolfraim LA, Fernandez TM, Mamura M, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med. 2004;351:552-559.
54. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006; 125:929-941.
55. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
56. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110:986-993.
57. Gastinne T, Vigant F, Lavenu-Bombled C, et al. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. Exp Hematol. 2007;35: 64-74.
58. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783-2810.
59. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3:1011-1022.